<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">39450339</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2235-2988</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in cellular and infection microbiology</Title><ISOAbbreviation>Front Cell Infect Microbiol</ISOAbbreviation></Journal><ArticleTitle>Editorial: Antiviral monoclonal antibody therapies.</ArticleTitle><Pagination><StartPage>1484448</StartPage><MedlinePgn>1484448</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1484448</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fcimb.2024.1484448</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Florez</LastName><ForeName>Catalina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Henry M. Jackson Foundation, Bethesda, MD, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>U.S Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haslwanter</LastName><ForeName>Denise</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jangra</LastName><ForeName>Rohit K</ForeName><Initials>RK</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence for Emerging Viral Threats, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Applied Immunology and Pathological Processes, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Cell Infect Microbiol</MedlineTA><NlmUniqueID>101585359</NlmUniqueID><ISSNLinking>2235-2988</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Editorial on the Research Topic Antiviral monoclonal antibody therapies</RefSource></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antiviral</Keyword><Keyword MajorTopicYN="N">bispecific Ab</Keyword><Keyword MajorTopicYN="N">monoclonal Abs</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>4</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39450339</ArticleId><ArticleId IdType="pmc">PMC11499238</ArticleId><ArticleId IdType="doi">10.3389/fcimb.2024.1484448</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pantaleo G., Correia B., Fenwick C., Joo V. S., Perez L. (2022). Antibodies to combat viral infections: development strategies and progress. Nat. Rev. Drug Discovery 21, 676–696. doi: 10.1038/s41573-022-00495-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-022-00495-3</ArticleId><ArticleId IdType="pmc">PMC9207876</ArticleId><ArticleId IdType="pubmed">35725925</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>